NCT04377659: A reported trial by Memorial Sloan Kettering Cancer Center
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04377659 |
|---|---|
| Title | A Phase II Study of IL-6 Receptor Antagonist Tocilizumab to Prevent Respiratory Failure and Death in Patients With Severe COVID-19 Infection |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 1, 2020 |
| Completion date | Oct. 28, 2022 |
| Required reporting date | Oct. 28, 2023, midnight |
| Actual reporting date | May 9, 2023 |
| Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
| Days late | None |